Aarti Drugs Ltd. shows a mixed performance in comparison to its peers in the Pharmaceuticals & Drugs sector. While it exhibits lower revenue growth and profitability metrics compared to several competitors, its debt levels are manageable, suggesting a stable positioning. Companies like Cipla and Dr. Reddy's lead in profitability, while Aarti presents a value opportunity with its relatively lower valuation metrics.

• • Aarti Drugs has a manageable debt-equity ratio of 0.4389, indicating lower financial risk.
• • Its revenue growth has been negative YoY at -5.6%, suggesting current operational challenges.
• • Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit significantly higher profitability with ROE above 16% and PE ratios suggesting overvaluation in the market.